Issue 4/2011
Content (23 Articles)
A novel structural derivative of natural alkaloid ellipticine, MDPSQ, induces necrosis in leukemic cells
M. S. Shahabuddin, Mridula Nambiar, Balaji T. Moorthy, Prakruthi L. Naik, Bibha Choudhary, Gopal M. Advirao, Sathees C. Raghavan
Potent anti-tumor activity of a macrocycle-quinoxalinone class pan-Cdk inhibitor in vitro and in vivo
Hiroshi Hirai, Ikuko Takahashi-Suziki, Toshiyasu Shimomura, Kazuhiro Fukasawa, Takumitsu Machida, Toru Takaki, Makiko Kobayashi, Tomohiro Eguchi, Hiroko Oki, Tsuyoshi Arai, Koji Ichikawa, Shinichi Hasako, Tsutomu Kodera, Nobuhiko Kawanishi, Yoko Nakatsuru, Hidehito Kotani, Yoshikazu Iwasawa
Effects of the microtubule stabilizing agent peloruside A on the proteome of HL-60 cells
Anja Wilmes, Pisana Rawson, Lifeng Peng, Danyl McLauchlan, Peter T. Northcote, T. William Jordan, John H. Miller
AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo
Mylin A. Torres, Uma Raju, David Molkentine, Oliver Riesterer, Luka Milas, K. Kian Ang
Cribrostatin 6 induces death in cancer cells through a reactive oxygen species (ROS)-mediated mechanism
Mirth T. Hoyt, Rahul Palchaudhuri, Paul J. Hergenrother
LYP, a novel bestatin derivative, inhibits cell growth and suppresses APN/CD13 activity in human ovarian carcinoma cells more potently than bestatin
Jian-Jun Gao, Zu-Hua Gao, Cui-Rong Zhao, Yi Yuan, Shu-Xiang Cui, Xiao-Fan Zhang, Yan-Na Cheng, Wen-Fang Xu, Wei Tang, Xian-Jun Qu
A natural compound, methyl angolensate, induces mitochondrial pathway of apoptosis in Daudi cells
Kishore K. Chiruvella, Sathees C. Raghavan
The anti-proliferative side effects of AEE788, a tyrosine kinase inhibitor blocking both EGF- and VEGF-receptor, are liver-size-dependent after partial hepatectomy in rats
Meihong Deng, Hai Huang, Hao Jin, Olaf Dirsch, Uta Dahmen
Anticancer activity and mode of action of titanocene C
Ulrike Olszewski, James Claffey, Megan Hogan, Matthias Tacke, Robert Zeillinger, Patrick J. Bednarski, Gerhard Hamilton
Peloruside A inhibits microtubule dynamics in a breast cancer cell line MCF7
Ariane Chan, Peter M. Andreae, Peter T. Northcote, John H. Miller
Thioredxin reductase inhibitor ethaselen increases the drug sensitivity of the colon cancer cell line LoVo towards cisplatin via regulation of G1 phase and reversal of G2/M phase arrest
Jia-ning Fu, Jing Li, Qiang Tan, Han-wei Yin, Kun Xiong, Tian-yu Wang, Xiao-yuan Ren, Hui-hui Zeng
Baicalin induces human mucoepidermoid carcinoma Mc3 cells apoptosis in vitro and in vivo
Xiao-Fang Xu, Bo-Lei Cai, Su-Min Guan, Yan Li, Jun-Zheng Wu, Yong Wang, Bin Liu
B1, a novel naphthalimide-based DNA intercalator, induces cell cycle arrest and apoptosis in HeLa cells via p53 activation
Xin Liang, Aibin Wu, Yufang Xu, Ke Xu, Jianwen Liu, Xuhong Qian
Suppressive effects of liquid crystal compounds on the growth of the A549 human lung cancer cell line
Yuuka Takahashi, Masaharu Hazawa, Kenji Takahashi, Ayumi Nishizawa, Atsushi Yoshizawa, Ikuo Kashiwakura
Anoikis induction and metastasis suppression by a new integrin αvβ3 inhibitor in human melanoma cell line M21
Yongci Zhang, Ming Yang, Qing Ji, Dongmei Fan, Hui Peng, Chunzheng Yang, Dongsheng Xiong, Yuan Zhou
A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human αv integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer
Franklin M. Chu, Joel Picus, Paula M. Fracasso, Robert Dreicer, Zhihui Lang, Brenda Foster
Escalating weekly doses of cetuximab and correlation with skin toxicity: A phase I study
Cheryl Ho, Randeep Sangha, Laurel Beckett, Michael Tanaka, Derick H. Lau, Daniel B. Eisen, Rachel A. Burich, Paul Luciw, Imran Khan, Philip C. Mack, David R. Gandara, Angela M. Davies
Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS
Kohei Shitara, Tomoya Yokota, Daisuke Takahari, Takashi Shibata, Takashi Ura, Setsuo Utsunomiya, Yoshitaka Inaba, Hidekazu Yamaura, Yozo Sato, Mina Najima, Hiroki Kawai, Masahiro Tajika, Akira Sawaki, Yasushi Yatabe, Kei Muro
A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer
Bassel Fuad El-Rayes, Philip A. Philip, Fazlul H. Sarkar, Anthony F. Shields, Ann Marie Ferris, Kenneth Hess, Ahmad O. Kaseb, Milind M. Javle, Gauri R. Varadhachary, Robert A. Wolff, James L. Abbruzzese
Factual understanding of randomized clinical trials: a multicenter case-control study in cancer patients
Tanguy Leroy, Véronique Christophe, Nicolas Penel, Pascal Antoine, Stéphanie Clisant
The notorious “drug lag” for oncology drugs in Japan
Kan Yonemori, Akihiro Hirakawa, Masashi Ando, Taizo Hirata, Mayu Yunokawa, Chikako Shimizu, Noriyuki Katsumata, Kenji Tamura, Yasuhiro Fujiwara
Proposal for size justification of expanded cohort at phase-2-recommended dose
Nicolas Penel, Charles Fournier, Jocelyne Bérille
Avascular necrosis of the femoral head: a rare class-effect of anti-VEGF agents
Olivier Mir, Romain Coriat, Thomas Gregory, Stanislas Ropert, Bertrand Billemont, François Goldwasser